Robin Sitver

Vice President of Corporate Development
Robin Sitver joined Alume Biosciences as Vice President of Corporate Development after 40 years of experience at Pfizer and J&J, focused on mergers, acquisitions, licensing, divestitures, finance, marketing, internal operations and information technology. She has worked in pharmaceuticals, medical devices, animal health and consumer products and has led over 60 transactions in more than 80 countries. Prior to her departure from J&J, Robin led strategic options for the diabetes business resulting in several deals for diabetes devices, including a transaction with a start-up company for a pre-market device and the $2.1 billion divestiture of Lifescan, one of J&J’s largest and most complex transactions.

Robin has broad based health care experience in all phases – growth, transition and turn-around in the fields of medical device, consumer, pharmaceuticals and animal health. She believes the difference between the success and failure of a deal is relationships, trust, strategic vision and careful planning that then leads to flawless execution.

Robin received her BA from Brandeis University (Magna Cum Laude with High honors in Computer Science) and her MBA from the Wharton School, University of Pennsylvania (MBA with Distinction, Beta Gamma Sigma).